Evidence map›Paper›PMID 26341226›Full record

ArticleJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale2015

Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.

M Elise R Graham, Robert D Hart, Susan Douglas, Fawaz M Makki, Devanand Pinto, Angela L Butler, Martin Bullock, Matthew H Rigby, Jonathan R B Trites, S Mark Taylor and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. The Blood Biomarkers of Thyroid Cancer.Cancer management and research · 2020
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

M Elise R GrahamDivision of Otolaryngology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. elise.graham@dal.ca.
Robert D HartDivision of Otolaryngology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. drrobhart@gmail.com.
Susan DouglasNRC Human Health Therapeutics, Oxford Street, Halifax, NS, Canada. susan.douglas@nrc-cnrc.gc.ca.
Fawaz M MakkiDivision of Otolaryngology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. f50_fawaz@hotmail.com.
Devanand PintoNRC Human Health Therapeutics, Oxford Street, Halifax, NS, Canada. Dev.Pinto@nrc-cnrc.gc.ca.
Angela L ButlerDivision of Otolaryngology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. butler.angela@rocketmail.com.
Martin BullockDivision of Anatomical Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. martin.bullock@cdha.nshealth.ca.
Matthew H RigbyDivision of Otolaryngology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. mhrigby@dal.ca.
Jonathan R B TritesDivision of Otolaryngology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. jonathan.trites@cdha.nshealth.ca.
S Mark TaylorDivision of Otolaryngology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada. smarktaylor@eastlink.ca.
Rama SinghNRC Human Health Therapeutics, Oxford Street, Halifax, NS, Canada. rama.singh@nrc-cnrc.gc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPapillary thyroid cancer (PTC) is increasing in incidence. Fine needle aspiration is the gold standard for diagnosis, but results can be indeterminate. Identifying tissue and serum biomarkers, like microRNA, is therefore desirable. We sought to identify miRNA that is differentially expressed in the serum of patients with PTC.

methodsSerum miRNA was quantified in 31 female thyroidectomy patients: 13 with benign disease and 18 with PTC. qPCR results were compared for significant fold-changes in 175 miRNAs, against a pooled control.

results128 miRNA qualified for analysis. There were identifiable fold-changes in miRNA levels between benign and control, and between PTC and control. There were statistically significant fold changes in the level of four miRNAs between benign and PTC: hsa-miR-146a-5p and hsa-miR-199b-3p were down-regulated, while hsa-let7b-5p and hsa-miR-10a-5p were up-regulated.

conclusionsMicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorBiopsy, Fine-NeedleCarcinomaCarcinoma, PapillaryFemaleHumansMicroRNAsPrognosisReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmThyroid Cancer, PapillaryThyroid DiseasesThyroid GlandThyroid NeoplasmsBiomarkers, TumorMicroRNAsMIRN10 microRNA, humanMIRN146 microRNA, humanmirn199 microRNA, humanRNA, Neoplasm

Identifiers

PMID26341226
PMCPMC4560924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.